Variables
Total cohort (n=18)
Hypoinflammatory low viral load (n=10)
Hyperinflammatory (n=2)
Hypoinflammatory low viral load (n=1)
Age, mean ± SD, years 68 ± 8 65 ±7.6 77± 2.8 73
Male Gender 50% (9/18) 30% 100% 0
African American race 16.7% (3/18) 20% 0 0
Immunosuppression 33.3% (6/18) 30% 50% 100%
Body mass index 33.8 ± 12.3 34.1±2.6 23.8±2.6 43.7
Diabetes mellitus 77.8% (14/18) 70% (7/10) 100% (2/2) 100% (1/1)
Days of intubation prior to BAL, mean ±SD 3.6 ± 3.6 3.3±2.1 4±4.2 1
Days from symptoms to BAL 13.6 ± 7.8 13.8±7.5 13.5±2.1 19
Dexamethasone prior to BAL 100% (18/18) 100% (10/10) 100% (2/2) 100% (1/1)
Tocilizumab prior to BAL 0 0 50% (1/2) 0
Remdesivir prior to BAL 55.6% (10/18) 50% (5/10) 50% (1/2) 100% (1/1)
Max temperature*, mean ± SD, 0C 37.7 ±1.1 37.4 ±0.8 38.3 ±1.1 40.1
Vasopressors* 72.2% (13/18) 70% (7/10) 100% (2/2) 0 (0/1)
Min PaO2/FiO2* 161.4 ± 93.2 168.7±120.7 101.2±18.6 148
CRP*, mean±SD, mg/L 155.2 ± 117.1 117.2±72.8 141.4±90.8 Not available
Max WBC*, mean ± SD, cells/µL 13.3 ± 6.3 12.9±5.6 13.4±3.5 7.7
Min lymphocyte count*, mean ± SD cells/µL 0.7 ± 0.4 0.5±0.3 1.2±0.6 0.5
BAL neutrophil % 38.5 ± 29.8 31±29.2 14 38
BAL lymphocyte % 8.4 ± 8.7 8±7.5 5 28
Ct value, mean ± SD 22 ± 6.5 23.4±5.6 23.6±6.2 14.4
IL-6 plasma, mean ± SD, pg/ml 1630.7±5383 160.4±306.6 9778.1±13782.8 38.5
IFN-γ plasma, mean ± SD, pg/ml 0.7±0.2 0.6±0 1±0.3 0.6
IL-1β plasma, mean ± SD, pg/ml 0.87±0.8 0.7±0.5 1.9±1.2 0.2
IL-8 plasma, mean ± SD, pg/ml 48.4±42.9 40.4±39.2 44.9±6.6 135.1
IL-10 plasma, mean ± SD, pg/ml 75±178.3 93.3±201.9 14.7±20.1 12.7
IL-12 plasma, mean ± SD, pg/ml 42.5±29.1 37.9±30 71.3±8.1 31.6
MIP-1β plasma, mean ± SD, pg/ml 223.7±470.7 83.3±62.7 151±1208.5 1773.2
MCP-1 plasma, mean ± SD, pg/ml 994.5±759.7 978.2±848.9 955±613.3 1237.5
IP-10 plasma, mean ± SD, pg/ml 183.3±229.6 111.9±67.3 613.5±386.4 37.8
Ventilator- free days, mean ± SD 1.8 +/- 2.9 1.7±2.9 1.5±2.1 0
Length of stay, mean ± SD, days 31.1 ± 15.6 29.9±14.2 38±15.6 8
Mortality 66.7% (12/18) 80% (8/10) 50% (1/2) 100% (1/1)